Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources. Diabetic kidney disease (DKD) remains a significant cause of end-stage renal failure in the patients of many countries and is also associate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	diabetes mellitus diabetic kidney disease glucagon-like peptide 1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/d917d0f44dee4e3b8116df39d5037ef2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d917d0f44dee4e3b8116df39d5037ef2
record_format	dspace
spelling	oai:doaj.org-article:d917d0f44dee4e3b8116df39d5037ef22021-11-14T09:00:23ZNephroprotective potential of glucagon-like peptide-1 receptor agonists2072-03512072-037810.14341/DM12379https://doaj.org/article/d917d0f44dee4e3b8116df39d5037ef22020-04-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12379https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources. Diabetic kidney disease (DKD) remains a significant cause of end-stage renal failure in the patients of many countries and is also associated with a high risk of cardiovascular pathology and mortality. The variety of clinical phenotypes of DKD in patients with type 2 diabetes mellitus (DM2) occurring due to a variety of pathogenetic factors and the characteristics of the evolution of complications under the influence of contemporary therapeutic methods, has been a special subject of discussion in recent years. Optimal control of the level of glycaemia and hypertension and timely blockade of the renin–angiotensin–aldosterone system do not provide sufficient protection for the kidneys. Over the recent decade, the nephroprotective potential of a group of modern anti-hyperglycaemic agents, i.e., glucagon-like peptide 1 receptor agonists (GLP1 RA) has been actively discussed. GLP1 RA have proven to be quite effective in controlling glycaemia and metabolic syndrome components (weight, systolic blood pressure and lipid profile) and in significantly reducing the risk of the primary, three-component endpoint (major adverse cardiac events: cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) according to large studies on cardiovascular safety. The renal effects of GLP1 RA are attributed to a wide range of direct and indirect effects of glucagon-like peptide-1 on renal structures and functions owing to their anti-inflammatory, anti-oxidant and anti-apoptotic properties.Minara S. ShamkhalovaIgor A. SklyanikMarina V. ShestakovaEndocrinology Research Centrearticlediabetes mellitusdiabetic kidney diseaseglucagon-like peptide 1 receptor agonistsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 1, Pp 56-64 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus diabetic kidney disease glucagon-like peptide 1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus diabetic kidney disease glucagon-like peptide 1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627 Minara S. Shamkhalova Igor A. Sklyanik Marina V. Shestakova Nephroprotective potential of glucagon-like peptide-1 receptor agonists
description	Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources. Diabetic kidney disease (DKD) remains a significant cause of end-stage renal failure in the patients of many countries and is also associated with a high risk of cardiovascular pathology and mortality. The variety of clinical phenotypes of DKD in patients with type 2 diabetes mellitus (DM2) occurring due to a variety of pathogenetic factors and the characteristics of the evolution of complications under the influence of contemporary therapeutic methods, has been a special subject of discussion in recent years. Optimal control of the level of glycaemia and hypertension and timely blockade of the renin–angiotensin–aldosterone system do not provide sufficient protection for the kidneys. Over the recent decade, the nephroprotective potential of a group of modern anti-hyperglycaemic agents, i.e., glucagon-like peptide 1 receptor agonists (GLP1 RA) has been actively discussed. GLP1 RA have proven to be quite effective in controlling glycaemia and metabolic syndrome components (weight, systolic blood pressure and lipid profile) and in significantly reducing the risk of the primary, three-component endpoint (major adverse cardiac events: cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) according to large studies on cardiovascular safety. The renal effects of GLP1 RA are attributed to a wide range of direct and indirect effects of glucagon-like peptide-1 on renal structures and functions owing to their anti-inflammatory, anti-oxidant and anti-apoptotic properties.
format	article
author	Minara S. Shamkhalova Igor A. Sklyanik Marina V. Shestakova
author_facet	Minara S. Shamkhalova Igor A. Sklyanik Marina V. Shestakova
author_sort	Minara S. Shamkhalova
title	Nephroprotective potential of glucagon-like peptide-1 receptor agonists
title_short	Nephroprotective potential of glucagon-like peptide-1 receptor agonists
title_full	Nephroprotective potential of glucagon-like peptide-1 receptor agonists
title_fullStr	Nephroprotective potential of glucagon-like peptide-1 receptor agonists
title_full_unstemmed	Nephroprotective potential of glucagon-like peptide-1 receptor agonists
title_sort	nephroprotective potential of glucagon-like peptide-1 receptor agonists
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/d917d0f44dee4e3b8116df39d5037ef2
work_keys_str_mv	AT minarasshamkhalova nephroprotectivepotentialofglucagonlikepeptide1receptoragonists AT igorasklyanik nephroprotectivepotentialofglucagonlikepeptide1receptoragonists AT marinavshestakova nephroprotectivepotentialofglucagonlikepeptide1receptoragonists
_version_	1718429493852372992

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Ejemplares similares